European Medicines Agency – EMA

which is issued by the European Commission. If granted， scientific advice programme and incentives， this enables them to market the medicine concerned throughout the EU and the EEA. Given thewide-ranging scope of the centralised procedure， it facilitates research into new medicines and encourages development， The European Medicines Agency (EMA) protects and promotes human and animal health by evaluating and monitoring medicines within the European Union (EU) and the European Economic Area (EEA). What it does The Agency's main responsibilities are authorising and monitoring medicines in the EU. Companies apply to it for a single marketing authorisation， most genuinely innovative medicines marketed in Europe are authorised by the EMA. The Agency fulfils its responsibilities by: facilitating the development of medicines access to them evaluating applications for marketing authorisations monitoring the safety of medicines throughout their lifecycle providing information to healthcare professionals patients Who benefits The EMA's work benefits: patients healthcare professionals academics pharmaceutical companies medicine developers health policymakers Through its scientific guidelines， thereby translating progress in medical science into medicines with real health benefits for patients. In particular， it promotes the development of medicines for children and drugs to tackle rare diseases. Further information Regulatory information on human medicines Regulatory information on veterinary medicines Partners networks ，。